LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder
As cannabis legalization continues to spread across the United States, average Δ9-tetrahydrocannabinol concentrations in recreational products have significantly increased, and no prior study has evaluated effective treatments to reduce cannabis use among high potency cannabis users. Some research h...
Gespeichert in:
Veröffentlicht in: | PloS one 2024-09, Vol.19 (9), p.e0308262 |
---|---|
Hauptverfasser: | , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 9 |
container_start_page | e0308262 |
container_title | PloS one |
container_volume | 19 |
creator | Bidwell, L Cinnamon Martin-Willett, Renee Melendez, Samantha N Rosa, Luiza Giordano, Gregory Hutchison, Kent E Bryan, Angela D |
description | As cannabis legalization continues to spread across the United States, average Δ9-tetrahydrocannabinol concentrations in recreational products have significantly increased, and no prior study has evaluated effective treatments to reduce cannabis use among high potency cannabis users. Some research has found that the non-intoxicating cannabinoid cannabidiol reduces cannabis use and cannabis use disorder-related symptoms, such as affective disturbance and withdrawal. Results of these studies are promising but limited to synthetic or isolated forms of cannabidiol.
Conduct a placebo-controlled randomized control trial comparing the effects of hemp-derived cannabidiol on reducing Δ9-tetrahydrocannabinol use in concentrate users with cannabis use disorder.
Design. Double-blind, three-arm randomized placebo-controlled trial. Setting. University in the Denver-Boulder, CO, USA area. Study population. Community members who are heavy, stable cannabis concentrate users that meet criteria for at least moderate cannabis use disorder and are seeking to decrease or stop cannabis use. Data. Self-report demographics, substance use, and mental health characteristics, blood and urine based biomarkers and anthropometrics. Outcomes. Affective, physiological, and physical withdrawal symptoms, Δ9-tetrahydrocannabinol use. Analysis. Three-group ANOVAs and χ2 tests will be used to compare baseline variables between groups. Characteristics that differ between groups will be evaluated as potential covariates in subsequent analyses. A multilevel modeling framework will be used for primary outcome analysis to account for the repeated observations nested within participants over time. Pairwise post-hoc simple effects tests will be conducted to confirm patterns of differences.
ClinicalTrials.gov NCT06107062. |
doi_str_mv | 10.1371/journal.pone.0308262 |
format | Article |
fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3111459108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A810663216</galeid><doaj_id>oai_doaj_org_article_4cbe26e092714d16bf208cf25da0a865</doaj_id><sourcerecordid>A810663216</sourcerecordid><originalsourceid>FETCH-LOGICAL-c572t-37d0df3b6b124561fb88ebf4a3daf3cab1f8bfac721947530bc472b1258cfc1c3</originalsourceid><addsrcrecordid>eNqNk11v0zAUhiMEYqPwDxBEQkJwkeKPxEm5QdPER6VKRWzj1vJn68qxi51MwH_gP-Os2dSgXSBfxDp53vccH_tk2XMI5hDX8N3O98ExO997p-YAgwYR9CA7hQuMCoIAfni0P8mexLgDoMINIY-zE7zAZYMJOc3-rNaXVxfv86_Bd154m2sfcpZL33OrCm6Nk_neMqG4z4V3XfDWKpkH5qRvze-07YJhNvc636p2X0gVzHWKCuYc40aa0bLbqkQq1rXKdQM9AjHvo8qliT4k6dPskWY2qmfjd5Zdffp4ef6lWK0_L8_PVoWoatQVuJZAaswJh6isCNS8aRTXJcOSaSwYh7rhmokawUVZVxhwUdYowVUjtIACz7KXB9-99ZGOnYwUQwjLagFBk4jlgZCe7eg-mJaFX9QzQ28CPmwoC50RVtFScIWIAgtUw1JCwjUCKQ-qJAOsIVXy-jBm63mrpEgdCMxOTKd_nNnSjb-mqZoSkmqo5s3oEPyPXsWOtiYKZS1zyveHwgkm4CbZq3_Q-483UhuWTmCc9imxGEzpWQMBIRglw1k2v4dKS6rWpNegtEnxieDtRDC8GPWz27A-Rrq8-Pb_7Pr7lH19xG4Vs902ett3xrs4BcsDKIKPMSh912UI6DA2t92gw9jQcWyS7MXxDd2JbucE_wW_JxQ0</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3111459108</pqid></control><display><type>article</type><title>LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Public Library of Science (PLoS) Journals Open Access</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><creator>Bidwell, L Cinnamon ; Martin-Willett, Renee ; Melendez, Samantha N ; Rosa, Luiza ; Giordano, Gregory ; Hutchison, Kent E ; Bryan, Angela D</creator><contributor>Carels, Vanessa</contributor><creatorcontrib>Bidwell, L Cinnamon ; Martin-Willett, Renee ; Melendez, Samantha N ; Rosa, Luiza ; Giordano, Gregory ; Hutchison, Kent E ; Bryan, Angela D ; Carels, Vanessa</creatorcontrib><description>As cannabis legalization continues to spread across the United States, average Δ9-tetrahydrocannabinol concentrations in recreational products have significantly increased, and no prior study has evaluated effective treatments to reduce cannabis use among high potency cannabis users. Some research has found that the non-intoxicating cannabinoid cannabidiol reduces cannabis use and cannabis use disorder-related symptoms, such as affective disturbance and withdrawal. Results of these studies are promising but limited to synthetic or isolated forms of cannabidiol.
Conduct a placebo-controlled randomized control trial comparing the effects of hemp-derived cannabidiol on reducing Δ9-tetrahydrocannabinol use in concentrate users with cannabis use disorder.
Design. Double-blind, three-arm randomized placebo-controlled trial. Setting. University in the Denver-Boulder, CO, USA area. Study population. Community members who are heavy, stable cannabis concentrate users that meet criteria for at least moderate cannabis use disorder and are seeking to decrease or stop cannabis use. Data. Self-report demographics, substance use, and mental health characteristics, blood and urine based biomarkers and anthropometrics. Outcomes. Affective, physiological, and physical withdrawal symptoms, Δ9-tetrahydrocannabinol use. Analysis. Three-group ANOVAs and χ2 tests will be used to compare baseline variables between groups. Characteristics that differ between groups will be evaluated as potential covariates in subsequent analyses. A multilevel modeling framework will be used for primary outcome analysis to account for the repeated observations nested within participants over time. Pairwise post-hoc simple effects tests will be conducted to confirm patterns of differences.
ClinicalTrials.gov NCT06107062.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0308262</identifier><identifier>PMID: 39348366</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adult ; Anxiety ; Biology and Life Sciences ; Biomarkers ; Cannabidiol ; Cannabidiol - therapeutic use ; Cannabinoids ; Cannabis ; Cannabis - chemistry ; Care and treatment ; Clinical trials ; Clinics ; Community ; Demographics ; Double-Blind Method ; Dronabinol - therapeutic use ; Drug abuse ; Drug dosages ; Drug withdrawal ; Evaluation ; Female ; Hemp ; Humans ; Male ; Marijuana ; Marijuana Abuse - drug therapy ; Medicine and Health Sciences ; Narcotics ; Patient outcomes ; People and Places ; Physiology ; Placebos ; Population studies ; Randomized Controlled Trials as Topic ; Recreational use ; Research and Analysis Methods ; Social networks ; Social Sciences ; Study Protocol ; Substance abuse ; Substance use ; Tetrahydrocannabinol ; THC ; Urine</subject><ispartof>PloS one, 2024-09, Vol.19 (9), p.e0308262</ispartof><rights>Copyright: © 2024 Bidwell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</rights><rights>COPYRIGHT 2024 Public Library of Science</rights><rights>2024 Bidwell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 Bidwell et al 2024 Bidwell et al</rights><rights>2024 Bidwell et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c572t-37d0df3b6b124561fb88ebf4a3daf3cab1f8bfac721947530bc472b1258cfc1c3</cites><orcidid>0000-0001-8940-8587 ; 0000-0001-6762-7586</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441658/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11441658/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,2102,2928,23866,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39348366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Carels, Vanessa</contributor><creatorcontrib>Bidwell, L Cinnamon</creatorcontrib><creatorcontrib>Martin-Willett, Renee</creatorcontrib><creatorcontrib>Melendez, Samantha N</creatorcontrib><creatorcontrib>Rosa, Luiza</creatorcontrib><creatorcontrib>Giordano, Gregory</creatorcontrib><creatorcontrib>Hutchison, Kent E</creatorcontrib><creatorcontrib>Bryan, Angela D</creatorcontrib><title>LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>As cannabis legalization continues to spread across the United States, average Δ9-tetrahydrocannabinol concentrations in recreational products have significantly increased, and no prior study has evaluated effective treatments to reduce cannabis use among high potency cannabis users. Some research has found that the non-intoxicating cannabinoid cannabidiol reduces cannabis use and cannabis use disorder-related symptoms, such as affective disturbance and withdrawal. Results of these studies are promising but limited to synthetic or isolated forms of cannabidiol.
Conduct a placebo-controlled randomized control trial comparing the effects of hemp-derived cannabidiol on reducing Δ9-tetrahydrocannabinol use in concentrate users with cannabis use disorder.
Design. Double-blind, three-arm randomized placebo-controlled trial. Setting. University in the Denver-Boulder, CO, USA area. Study population. Community members who are heavy, stable cannabis concentrate users that meet criteria for at least moderate cannabis use disorder and are seeking to decrease or stop cannabis use. Data. Self-report demographics, substance use, and mental health characteristics, blood and urine based biomarkers and anthropometrics. Outcomes. Affective, physiological, and physical withdrawal symptoms, Δ9-tetrahydrocannabinol use. Analysis. Three-group ANOVAs and χ2 tests will be used to compare baseline variables between groups. Characteristics that differ between groups will be evaluated as potential covariates in subsequent analyses. A multilevel modeling framework will be used for primary outcome analysis to account for the repeated observations nested within participants over time. Pairwise post-hoc simple effects tests will be conducted to confirm patterns of differences.
ClinicalTrials.gov NCT06107062.</description><subject>Adult</subject><subject>Anxiety</subject><subject>Biology and Life Sciences</subject><subject>Biomarkers</subject><subject>Cannabidiol</subject><subject>Cannabidiol - therapeutic use</subject><subject>Cannabinoids</subject><subject>Cannabis</subject><subject>Cannabis - chemistry</subject><subject>Care and treatment</subject><subject>Clinical trials</subject><subject>Clinics</subject><subject>Community</subject><subject>Demographics</subject><subject>Double-Blind Method</subject><subject>Dronabinol - therapeutic use</subject><subject>Drug abuse</subject><subject>Drug dosages</subject><subject>Drug withdrawal</subject><subject>Evaluation</subject><subject>Female</subject><subject>Hemp</subject><subject>Humans</subject><subject>Male</subject><subject>Marijuana</subject><subject>Marijuana Abuse - drug therapy</subject><subject>Medicine and Health Sciences</subject><subject>Narcotics</subject><subject>Patient outcomes</subject><subject>People and Places</subject><subject>Physiology</subject><subject>Placebos</subject><subject>Population studies</subject><subject>Randomized Controlled Trials as Topic</subject><subject>Recreational use</subject><subject>Research and Analysis Methods</subject><subject>Social networks</subject><subject>Social Sciences</subject><subject>Study Protocol</subject><subject>Substance abuse</subject><subject>Substance use</subject><subject>Tetrahydrocannabinol</subject><subject>THC</subject><subject>Urine</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>DOA</sourceid><recordid>eNqNk11v0zAUhiMEYqPwDxBEQkJwkeKPxEm5QdPER6VKRWzj1vJn68qxi51MwH_gP-Os2dSgXSBfxDp53vccH_tk2XMI5hDX8N3O98ExO997p-YAgwYR9CA7hQuMCoIAfni0P8mexLgDoMINIY-zE7zAZYMJOc3-rNaXVxfv86_Bd154m2sfcpZL33OrCm6Nk_neMqG4z4V3XfDWKpkH5qRvze-07YJhNvc636p2X0gVzHWKCuYc40aa0bLbqkQq1rXKdQM9AjHvo8qliT4k6dPskWY2qmfjd5Zdffp4ef6lWK0_L8_PVoWoatQVuJZAaswJh6isCNS8aRTXJcOSaSwYh7rhmokawUVZVxhwUdYowVUjtIACz7KXB9-99ZGOnYwUQwjLagFBk4jlgZCe7eg-mJaFX9QzQ28CPmwoC50RVtFScIWIAgtUw1JCwjUCKQ-qJAOsIVXy-jBm63mrpEgdCMxOTKd_nNnSjb-mqZoSkmqo5s3oEPyPXsWOtiYKZS1zyveHwgkm4CbZq3_Q-483UhuWTmCc9imxGEzpWQMBIRglw1k2v4dKS6rWpNegtEnxieDtRDC8GPWz27A-Rrq8-Pb_7Pr7lH19xG4Vs902ett3xrs4BcsDKIKPMSh912UI6DA2t92gw9jQcWyS7MXxDd2JbucE_wW_JxQ0</recordid><startdate>20240930</startdate><enddate>20240930</enddate><creator>Bidwell, L Cinnamon</creator><creator>Martin-Willett, Renee</creator><creator>Melendez, Samantha N</creator><creator>Rosa, Luiza</creator><creator>Giordano, Gregory</creator><creator>Hutchison, Kent E</creator><creator>Bryan, Angela D</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0001-8940-8587</orcidid><orcidid>https://orcid.org/0000-0001-6762-7586</orcidid></search><sort><creationdate>20240930</creationdate><title>LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder</title><author>Bidwell, L Cinnamon ; Martin-Willett, Renee ; Melendez, Samantha N ; Rosa, Luiza ; Giordano, Gregory ; Hutchison, Kent E ; Bryan, Angela D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c572t-37d0df3b6b124561fb88ebf4a3daf3cab1f8bfac721947530bc472b1258cfc1c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Anxiety</topic><topic>Biology and Life Sciences</topic><topic>Biomarkers</topic><topic>Cannabidiol</topic><topic>Cannabidiol - therapeutic use</topic><topic>Cannabinoids</topic><topic>Cannabis</topic><topic>Cannabis - chemistry</topic><topic>Care and treatment</topic><topic>Clinical trials</topic><topic>Clinics</topic><topic>Community</topic><topic>Demographics</topic><topic>Double-Blind Method</topic><topic>Dronabinol - therapeutic use</topic><topic>Drug abuse</topic><topic>Drug dosages</topic><topic>Drug withdrawal</topic><topic>Evaluation</topic><topic>Female</topic><topic>Hemp</topic><topic>Humans</topic><topic>Male</topic><topic>Marijuana</topic><topic>Marijuana Abuse - drug therapy</topic><topic>Medicine and Health Sciences</topic><topic>Narcotics</topic><topic>Patient outcomes</topic><topic>People and Places</topic><topic>Physiology</topic><topic>Placebos</topic><topic>Population studies</topic><topic>Randomized Controlled Trials as Topic</topic><topic>Recreational use</topic><topic>Research and Analysis Methods</topic><topic>Social networks</topic><topic>Social Sciences</topic><topic>Study Protocol</topic><topic>Substance abuse</topic><topic>Substance use</topic><topic>Tetrahydrocannabinol</topic><topic>THC</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bidwell, L Cinnamon</creatorcontrib><creatorcontrib>Martin-Willett, Renee</creatorcontrib><creatorcontrib>Melendez, Samantha N</creatorcontrib><creatorcontrib>Rosa, Luiza</creatorcontrib><creatorcontrib>Giordano, Gregory</creatorcontrib><creatorcontrib>Hutchison, Kent E</creatorcontrib><creatorcontrib>Bryan, Angela D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bidwell, L Cinnamon</au><au>Martin-Willett, Renee</au><au>Melendez, Samantha N</au><au>Rosa, Luiza</au><au>Giordano, Gregory</au><au>Hutchison, Kent E</au><au>Bryan, Angela D</au><au>Carels, Vanessa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2024-09-30</date><risdate>2024</risdate><volume>19</volume><issue>9</issue><spage>e0308262</spage><pages>e0308262-</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>As cannabis legalization continues to spread across the United States, average Δ9-tetrahydrocannabinol concentrations in recreational products have significantly increased, and no prior study has evaluated effective treatments to reduce cannabis use among high potency cannabis users. Some research has found that the non-intoxicating cannabinoid cannabidiol reduces cannabis use and cannabis use disorder-related symptoms, such as affective disturbance and withdrawal. Results of these studies are promising but limited to synthetic or isolated forms of cannabidiol.
Conduct a placebo-controlled randomized control trial comparing the effects of hemp-derived cannabidiol on reducing Δ9-tetrahydrocannabinol use in concentrate users with cannabis use disorder.
Design. Double-blind, three-arm randomized placebo-controlled trial. Setting. University in the Denver-Boulder, CO, USA area. Study population. Community members who are heavy, stable cannabis concentrate users that meet criteria for at least moderate cannabis use disorder and are seeking to decrease or stop cannabis use. Data. Self-report demographics, substance use, and mental health characteristics, blood and urine based biomarkers and anthropometrics. Outcomes. Affective, physiological, and physical withdrawal symptoms, Δ9-tetrahydrocannabinol use. Analysis. Three-group ANOVAs and χ2 tests will be used to compare baseline variables between groups. Characteristics that differ between groups will be evaluated as potential covariates in subsequent analyses. A multilevel modeling framework will be used for primary outcome analysis to account for the repeated observations nested within participants over time. Pairwise post-hoc simple effects tests will be conducted to confirm patterns of differences.
ClinicalTrials.gov NCT06107062.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>39348366</pmid><doi>10.1371/journal.pone.0308262</doi><tpages>e0308262</tpages><orcidid>https://orcid.org/0000-0001-8940-8587</orcidid><orcidid>https://orcid.org/0000-0001-6762-7586</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1932-6203 |
ispartof | PloS one, 2024-09, Vol.19 (9), p.e0308262 |
issn | 1932-6203 1932-6203 |
language | eng |
recordid | cdi_plos_journals_3111459108 |
source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Public Library of Science (PLoS) Journals Open Access; PubMed Central; Free Full-Text Journals in Chemistry |
subjects | Adult Anxiety Biology and Life Sciences Biomarkers Cannabidiol Cannabidiol - therapeutic use Cannabinoids Cannabis Cannabis - chemistry Care and treatment Clinical trials Clinics Community Demographics Double-Blind Method Dronabinol - therapeutic use Drug abuse Drug dosages Drug withdrawal Evaluation Female Hemp Humans Male Marijuana Marijuana Abuse - drug therapy Medicine and Health Sciences Narcotics Patient outcomes People and Places Physiology Placebos Population studies Randomized Controlled Trials as Topic Recreational use Research and Analysis Methods Social networks Social Sciences Study Protocol Substance abuse Substance use Tetrahydrocannabinol THC Urine |
title | LOTUS: Protocol for a double-blind placebo controlled randomized trial of hemp-derived cannabidiol for the treatment of cannabis use disorder |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T13%3A40%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LOTUS:%20Protocol%20for%20a%20double-blind%20placebo%20controlled%20randomized%20trial%20of%20hemp-derived%20cannabidiol%20for%20the%20treatment%20of%20cannabis%20use%20disorder&rft.jtitle=PloS%20one&rft.au=Bidwell,%20L%20Cinnamon&rft.date=2024-09-30&rft.volume=19&rft.issue=9&rft.spage=e0308262&rft.pages=e0308262-&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0308262&rft_dat=%3Cgale_plos_%3EA810663216%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3111459108&rft_id=info:pmid/39348366&rft_galeid=A810663216&rft_doaj_id=oai_doaj_org_article_4cbe26e092714d16bf208cf25da0a865&rfr_iscdi=true |